Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Certification Requirements Under FDAAA May Be “Time Bomb”

Executive Summary

The section of the FDA Amendments Act that requires companies to post information about their clinical trials contains a "hidden time bomb," according to I. Scott Bass, a partner at the law firm Sidley Austin
Advertisement

Related Content

Now-Mandatory Informed Consent Wording Won't Be Required Retroactively
Now-Mandatory Informed Consent Wording Won't Be Required Retroactively
Clinical Trial Certification: Companies Say IND Submissions Should Be Exempt
Clinical Trial Certification: Companies Say IND Submissions Should Be Exempt
Will Vytorin Fallout Include ENHANCEd Reporting Requirements For All Trials?
Will Vytorin Fallout Include ENHANCEd Reporting Requirements For All Trials?
FDAAA Cornucopia: REMS To Be Used Sparingly; Trial Database On Schedule
FDAAA Cornucopia: REMS To Be Used Sparingly; Trial Database On Schedule
Advertisement
UsernamePublicRestriction

Register

PS049330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel